Pliant Therapeutics (PLRX)
(Delayed Data from NSDQ)
$11.81 USD
-0.07 (-0.59%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $11.81 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Cash flow Statements
Fiscal Year End for Pliant Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -161.34 | -123.32 | -97.26 | -41.53 | -0.63 |
Depreciation/Amortization & Depletion | -3.15 | 0.02 | 1.54 | 1.31 | 1.11 |
Net Change from Assets/Liabilities | 1.25 | 4.22 | 6.92 | -1.21 | -5.06 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 46.87 | 24.46 | 13.37 | 4.16 | 1.83 |
Net Cash From Operating Activities | -116.36 | -94.63 | -75.44 | -37.27 | -2.75 |
Property & Equipment | -0.92 | -1.76 | -1.95 | -1.53 | -0.96 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -126.09 | -148.44 | 75.65 | -209.33 | -16.97 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -127.01 | -150.20 | 73.70 | -210.87 | -17.93 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 275.25 | 227.41 | 2.98 | 213.21 | 48.12 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.85 | -0.56 | -0.46 | 0.00 | -2.58 |
Net Cash from Financing Activities | 274.41 | 226.85 | 2.53 | 213.21 | 45.54 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 31.03 | -17.98 | 0.78 | -34.93 | 24.86 |
Cash at Beginning of Period | 33.68 | 51.67 | 50.88 | 85.81 | 60.95 |
Cash at End of Period | 64.72 | 33.68 | 51.67 | 50.88 | 85.81 |
Diluted Net EPS | -2.75 | -2.94 | -2.71 | -1.95 | -4.22 |
Fiscal Year End for Pliant Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -161.34 | -120.23 | -78.74 | -37.55 |
Depreciation/Amortization & Depletion | NA | -3.15 | -8.84 | -5.58 | -2.13 |
Net Change from Assets/Liabilities | NA | 1.25 | 0.64 | 3.08 | -3.13 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 46.87 | 37.16 | 26.21 | 12.53 |
Net Cash From Operating Activities | NA | -116.36 | -91.26 | -55.04 | -30.28 |
Property & Equipment | NA | -0.92 | -0.86 | -0.77 | -0.16 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | -126.09 | -158.07 | -196.42 | -174.05 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | -127.01 | -158.93 | -197.19 | -174.21 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 275.25 | 275.02 | 274.25 | 273.91 |
Issuance (Repayment) of Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | -0.85 | -0.83 | -0.76 | -0.59 |
Net Cash from Financing Activities | NA | 274.41 | 274.19 | 273.49 | 273.33 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | 31.03 | 23.99 | 21.27 | 68.84 |
Cash at Beginning of Period | NA | 33.68 | 33.69 | 33.69 | 33.69 |
Cash at End of Period | NA | 64.72 | 57.68 | 54.95 | 102.53 |
Diluted Net EPS | NA | -0.68 | -0.70 | -0.70 | -0.67 |